Abstracts Archive - Page 545 of 2607 - ACR Meeting Abstracts

Abstract Number: 127 • 2023 Pediatric Rheumatology Symposium
What’s in a Name? A20 Protein Expression in an in Vitro Model of A20 Haploinsufficiency
Patricia Pontes Aires¹, DANIELA GERENT PETRY PIOTTO¹, Andre Cunha¹, Sandro Perazzio² and Maria Teresa Terreri³, ¹Universidade Federal de São Paulo, São Paulo, Brazil, ²Universidade de So Paulo; Fleury Laboratories, São Paulo, Brazil, ³UNIFESP, São Paulo, Brazil
Background/Purpose: Tumor necrosis factor alpha (TNF-alpha) induced protein 3 gene, or TNFAIP3, encodes the A20 protein, an important regulator of the NF-κB pathway. Since its…
Abstract Number: 125 • 2023 Pediatric Rheumatology Symposium
Measurable Outcomes of an Ophthalmology and Rheumatology Coordinated Care Clinic
Catherine Lavallee¹, Sabrina Gmuca² and Melissa Lerman², ¹Virginia Tech Carilion School of Medicine, ROANOKE, VA, ²Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Non-infectious pediatric uveitis is a vision threatening disease whose treatment involves both ophthalmologists and rheumatologists.In other diseases necessitating multidisciplinary care, coordinated care clinics have…
Abstract Number: 122 • 2023 Pediatric Rheumatology Symposium
Juvenile Arthritis in Minnesota: Geospatial Variability and Environmental Exposures in Juvenile Idiopathic Arthritis
Colleen Correll¹, Austin Rau² and Jesse Berman², ¹University of Minnesota, Minneapolis, MN, ²University of Minnesota, Minneapolis
Background/Purpose: It is widely accepted that juvenile idiopathic arthritis (JIA) is caused by a combination of genetic and environmental factors, but the potential environmental triggers…
Abstract Number: 092 • 2023 Pediatric Rheumatology Symposium
Procalcitonin Levels in Patients with Juvenile Dermatomyositis Compared to Healthy Controls
Christopher Costin¹, Gabrielle Morgan², Lutfiyya Muhammad³, Amer Khojah⁴, Marisa Klein-Gitelman¹, Yvonne Lee⁵ and Lauren Pachman⁶, ¹Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ²Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, IL, ³Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Umm Al-Qura University, Makkah, Saudi Arabia, ⁵Northwestern University, Chicago, IL, ⁶Northwestern's Feinberg School of Medicine. Ann and Robert H. Lurie Children's Hospital of Chicago; Stanley Manne Children's Research Institute of Chicago, Lake Forest, IL
Background/Purpose: Patients with JDM are at increased risk of infection due to increased aspiration risk and immunosuppression. Procalcitonin (PCT) is a biomarker of infection, that…
Abstract Number: 105 • 2023 Pediatric Rheumatology Symposium
Awareness of Multisystem Inflammatory Syndrome in Children Among U.S. Parents: A Cross-Sectional Survey
Lyndsey Cole¹, E. Adrianne Hammershaimb², Yuanyuan Liang², Megan Hendrich³, Dhiman Das³, Robert Petrin³, James Campbell², Sean O'Leary¹ and Jessica Cataldi¹, ¹University of Colorado School of Medicine, Denver, CO, ²University of Maryland School of Medicine, Baltimore, MD, ³Ipsos US Public Affairs, Washington, DC
Background/Purpose: Little is known about parental awareness of multisystem inflammatory syndrome in children (MIS-C), a rare but severe sequela of SARS-CoV-2 infection. We sought to…
Abstract Number: 078 • 2023 Pediatric Rheumatology Symposium
Periodic Fever Syndrome and Myelodysplastic Syndrome: Possible Connections Between Two Disorders
Ivanna Romankevych¹, Nicole Torres², Imani Sanders¹, Laurent King¹ and Pedro Garcia Rodriguez¹, ¹Jackson Health System, University of Miami Miller School of Medicine, Miami, FL, ²University of Miami Miller School of Medicine, Miami, FL
Background/Purpose: Background: associations between autoimmune, immunodeficiency and hematological disorders are well known as well as with autoinflammatory conditions. Modern genetic testing allows to link these…
Abstract Number: 136 • 2023 Pediatric Rheumatology Symposium
Incidence and Disease Burden of Juvenile Idiopathic Arthritis and Rheumatoid Arthritis After Non-Pharmaceutical Interventions in the COVID-19 Era: A Nationwide Observational Study in Korea
Je Hee Shin¹, Jung Yoon Pyo², Minkyung Han³, Myeongjee Lee³, Sung Min Lim¹, Jee Yeon Baek¹, Ji Young Lee¹, Ji-Man Kang¹, InKyung Jung³ and Jong Gyun Ahn¹, ¹Severance Children's Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea, ²Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea, ³Department of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, Republic of Korea
Background/Purpose: Several countries have implemented non-pharmaceutical interventions (NPIs) against the coronavirus disease 2019 (COVID-19) pandemic. We investigated the impact of NPIs on the incidence of…
Abstract Number: 135 • 2023 Pediatric Rheumatology Symposium
Assessing Medication Adherence in JIA: Pilot Phase Results from a Single-Center Quality Improvement Initiative
Dori Abel¹, Joyce Chang², Jon Burnham³, Chen Kenyon⁴ and Sabrina Gmuca⁵, ¹Department of Pediatrics, Division of Rheumatology, Children’s Hospital of Philadelphia; PolicyLab, Children's Hospital of Philadelphia, Philadelphia, PA, ²Boston Children's Hospital, Boston, MA, ³Department of Pediatrics, Division of Rheumatology, Children’s Hospital of Philadelphia; Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ⁴Department of Pediatrics, University of Pennsylvania Perelman School of Medicine; PolicyLab, Children’s Hospital of Philadelphia, Philadelphia, PA; Leonard Davis Institute of Health Economics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ⁵Department of Pediatrics, Division of Rheumatology, Children’s Hospital of Philadelphia; Center for Pediatric Clinical Effectiveness, Children’s Hospital of Philadelphia; PolicyLab, Children's Hospital of Philadelphia; Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
Background/Purpose: Suboptimal medication adherence is a widespread problem in JIA. There are several unique features to medication adherence in JIA, including that the medications used…
Abstract Number: 123 • 2023 Pediatric Rheumatology Symposium
Development of Specific Classification Criteria for Juvenile System Sclerosis Patients: A Scoping Review
Ioana Dobre¹, Suzanne Li², Natalia Vasquez Canizares³, Barbara Reich⁴, Xurong Zhao⁵, Quinn McCormick⁶ and Marinka Twilt⁵, ¹Alberta Children's Hospital/University of Calgary, Calgary, AB, Canada, ²Hackensack Meridian School of Medicine, Joseph M. Sanzari Children's Hospital, Hackensack, NJ, ³Children's Hospital at Montefiore, New York, NY, ⁴Hackensack University Medical Center, Hackensack, NJ, ⁵Alberta Children's Hospital, Calgary, AB, Canada, ⁶Hackensack Medical Hospital Network, Hackensack, NJ
Background/Purpose: Juvenile systemic sclerosis (jSSc) is associated with one of the highest morbidity and mortality rate in pediatric rheumatology, yet care recommendations are based upon…
Abstract Number: 137 • 2023 Pediatric Rheumatology Symposium
Geographic Mapping of Adolescents with Rheumatic Disease: Racial and Ethnic Diversity by Texas County
Kristina Ciaglia¹, Chan-hee Jo², Yuhan Ma², Tracey Wright³ and Lorien Nassi¹, ¹University of Texas Southwestern, Dallas, TX, ²Scottish Rite Hospital for Children, Dallas, TX, ³University of Texas Southwestern, Scottish Rite Hospital for Children, Dallas, TX
Background/Purpose: Rheumatic disease disproportionately impacts specific racial and ethnic groups frequently, resulting in health care inequities. Health care disparities are prevalent within certain geographic areas…
Abstract Number: 117 • 2023 Pediatric Rheumatology Symposium
A Descriptive Study of Patients with Multisystem Inflammatory Syndrome in Children
Alexis Begezda, Penn State, State College, PA
Background/Purpose: Children with childhood-onset systemic lupus erythematosus (cSLE) experience more severe disease than their adult counterparts, in addition to high rates of clinical depressive symptoms…
Abstract Number: 132 • 2023 Pediatric Rheumatology Symposium
Quality Improvement Lessons in a New Practice
Farah Shaya, Sharon Bout-Tabaku and Buthaina Al-Adba, Sidra Medicine, Ar-Rayyan, Qatar
Background/Purpose: Children with Juvenile Idiopathic Arthritis (JIA) have better disease outcomes with current medications available, yet there is variability in these outcomes. Quality improvement (QI)…
Abstract Number: 120 • 2023 Pediatric Rheumatology Symposium
The Brazilian Registry of Juvenile Dermatomyositis (JDM): I- Onset Clinical Features and Disease Activity Scores by DAS-20 over 2-Years-Follow Up
Beatriz Carneiro¹, Adriana Elias¹, Teresa Robazzi², Ana Julia Moraes³, Sheila Oliveira⁴, Flavio Sztajnbok⁵, Luciana Carvalho⁶, Luciana Marques⁷, Silvana Sacchetti⁸, Maria Teresa Terreri⁹, Simone Appenzelle¹⁰, Roberto Marini¹¹, Andre Cavalcante¹², Marcia Bandeira¹³, Cristina Magalhaes¹⁴, Melissa Fraga¹⁵, Iloite Scheibel¹⁶, Isabela Daud¹, Darcisio Antonio¹⁷, Claudio Len¹⁸, Clovis Silva¹⁹, Taciana Fernandes¹⁷ and Claudia Magalhaes²⁰, ¹Instituto da Criança - Universidade de São Paulo (USP), São Paulo, Brazil, ²Universidade Federal da Bahia, Brazil, ³Universidade Federal do Para, Brazil, ⁴Universidade Federal do Rio de janeiro, Rio de Janeiro, ⁵Universidade Estadual do Rio de Janeiro, Rio de Janeiro, Brazil, ⁶Universidade de Sao Paulo- Ribeirao Preto, São Paulo, Brazil, ⁷Hospital Albert Sabin, Brazil, ⁸Santa Casa de Sao Paulo, Brazil, ⁹UNIFESP, São Paulo, Brazil, ¹⁰University of Campinas, Campinas, Sao Paulo, Brazil, ¹¹UNICAMP, São Paulo, Brazil, ¹²Hospital Materno-Infantil de Goiania, Brazil, ¹³Hospital Pequeno Principe- Curitiba, Brazil, ¹⁴Hospital Jose de Alencar - Brasilia, Brazil, ¹⁵Hospital Darcy Vargas, Brazil, ¹⁶Hospital Conceição de Porto Alegre, Brazil, ¹⁷Universidade Estadual Paulista (UNESP) Botucatu, Brazil, ¹⁸Universidade Federal de São Paulo - Unifesp, São Paulo, Brazil, ¹⁹Universidade de São Paulo, São Paulo, Brazil, ²⁰São Paulo State University, Pediatric Rheumatology Division, Botucatu, Brazil
Background/Purpose: A national registry was set up, enrolling new onset JDM cases in 18 hospitals, during 3-years (2015-2018) with 2-years follow up, in a low…
Abstract Number: 126 • 2023 Pediatric Rheumatology Symposium
Facilitating Peer-to-Peer Conversations Around Key Clinical Trial Recruitment Barriers in the Limit-JIA Trial Using Low-Fidelity Video Capture
Melanie Kohlheim¹, Eveline Wu², Laura Schanberg³, Vincent Del Gaizo¹, Catherine Lavallee⁴, Marc Natter⁵, Katie Clem⁶, Brian Shakley⁶ and Kevin Urban⁷, ¹CARRA, Washington, DC, ²UNC Chapel Hill, Chapel Hill, NC, ³Duke University Medical Center, Durham, NC, ⁴Virginia Tech Carilion School of Medicine, ROANOKE, VA, ⁵Boston Children's Hospital, Boston, MA, ⁶LIFT 1428, Llc, Ooltewah, TN, ⁷Business Coaching for Creatives, New York, NY
Background/Purpose: The LIMIT-JIA trial aims to study if early abatacept treatment can prevent disease extension in children with recent-onset, uncomplicated, and oligoarticular or limited JIA.…
Abstract Number: 116 • 2023 Pediatric Rheumatology Symposium
Clinical Significance of Anti-Scl-70 Antibodies in Pediatric Lupus Patients: A Single Center Cohort
Dawn Janysek¹, Yiressy Pina², Danielle Guffey³ and Marietta De Guzman¹, ¹Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ²Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ³Baylor College of Medicine, Houston, TX
Background/Purpose: Production of autoantibodies is a hallmark of SLE, with ANAs as a required diagnostic feature and anti-dsDNA and anti-Smith antibodies being disease-specific. Anti-Scl-70 antibodies…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].